Upexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Upexi (NASDAQ:UPXI - Free Report) from a neutral rating to an overweight rating in a research note released on Monday morning, Marketbeat.com reports. They currently have $16.00 price objective on the stock.

Separately, Wall Street Zen upgraded shares of Upexi to a "hold" rating in a research note on Friday, May 30th.

Upexi Trading Up 12.5%

Shares of NASDAQ UPXI traded up $1.20 during midday trading on Monday, reaching $10.79. 501,631 shares of the stock were exchanged, compared to its average volume of 884,136. Upexi has a 52-week low of $1.90 and a 52-week high of $22.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.24 and a current ratio of 0.37. The stock has a 50 day moving average price of $9.96 and a 200-day moving average price of $5.73.

Upexi (NASDAQ:UPXI - Get Free Report) last released its earnings results on Friday, May 16th. The company reported ($2.87) earnings per share (EPS) for the quarter. Upexi had a negative net margin of 135.86% and a negative return on equity of 535.19%. The company had revenue of $3.16 million during the quarter.

Insider Transactions at Upexi

In other Upexi news, Director Gene Salkind bought 241,229 shares of the company's stock in a transaction on Thursday, April 17th. The shares were bought at an average cost of $2.28 per share, with a total value of $550,002.12. Following the completion of the acquisition, the director now owns 365,127 shares of the company's stock, valued at approximately $832,489.56. This trade represents a 194.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew James Norstrud bought 43,860 shares of the company's stock in a transaction on Thursday, April 17th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $100,000.80. Following the completion of the acquisition, the chief financial officer now directly owns 59,138 shares of the company's stock, valued at $134,834.64. This trade represents a 287.08% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 942,984 shares of company stock valued at $2,150,004. Corporate insiders own 31.60% of the company's stock.

Hedge Funds Weigh In On Upexi

A hedge fund recently bought a new stake in Upexi stock. Bank of Montreal Can purchased a new position in shares of Upexi, Inc. (NASDAQ:UPXI - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,008 shares of the company's stock, valued at approximately $36,000. Bank of Montreal Can owned about 0.81% of Upexi as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 5.68% of the company's stock.

About Upexi

Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.